Two-year abatacept retention rate in clinical practice in the French ACTION cohort - 06/09/19

Doi : 10.1016/j.jbspin.2019.07.006

Xavier Mariette ^a,⁎ , Thierry Schaeverbeke ^g, Philippe Gaudin ^d,^e, Mélanie Chartier ^h, Julia Heitzmann ⁱ, Virginie Vannier-Moreau ^j, Pascal Hilliquin ^f, Alain Cantagrel ^b,^c
^a Université Paris-Sud, AP–HP, Hôpitaux universitaires Paris-Sud, Inserm UMR1184, 94270 Le Kremlin-Bicêtre, France
^b Centre de rhumatologie, hôpital Pierre-Paul-Riquet, CHU de Toulouse, place du Dr Baylac, TSA 40 031, 31059 Toulouse cedex 9, France
^c CPTP, Inserm UMR 1043, CHU Purpan, BP 3028, 31024 Toulouse cedex 3, France
^d Département de rhumatologie, Hôpital Sud, CHU de Grenoble, 38130 Echirolles, France
^e GREPI - UGA EA 7408, Domaine de la Merci, 38700 La Tronche, France
^f Département de rhumatologie, Centre Hospitalier Sud Francilien, 91100 Corbeil-Essonnes, France
^g Département de rhumatologie, Hôpital Pellegrin, place Amélie Raba-Léon, 33000 Bordeaux, France
^h Département « Global Clinical Trial Strategy & Operations », Bristol-Myers Squibb, 92500 Rueil-Malmaison, France
ⁱ Excelya, 92100 Boulogne-Billancourt, France
^j Médical ImmunoScience/Rhumatologie, Bristol-Myers Squibb, 92500 Rueil-Malmaison, France

^⁎Corresponding author at: 78, rue du Général Leclerc, Le Kremlin-Bicêtre 94270, France.78, rue du Général LeclercLe Kremlin-Bicêtre 94270France

Sous presse. Épreuves corrigées par l'auteur. Disponible en ligne depuis le Friday 06 September 2019
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder

Abstract

Objectives

Abatacept retention rates were evaluated in the French cohort in the prospective ACTION study (2010–2013), which included patients with moderate-to-severe rheumatoid arthritis managed in everyday clinical practice and started on intravenous abatacept therapy.

Methods

Two-year abatacept retention rates were evaluated in 455 patients classified according to treatment line, body mass index (BMI), and status for rheumatoid factor (RF) and anti-citrullinated peptide antibody (ACPA).

Results

After 2 years, the overall abatacept retention rate was 44%. The retention rate was non-significantly higher in the patients with vs. without a history of unresponsiveness to at least one biologic (48.1% vs. 41.8%, respectively). No significant retention rate differences were found across BMI categories (444 patients; <25, 45.5%; ≥25 to <30, 48.9%; and ≥30, 36.6%). Neither were any significant differences demonstrated according to RF and ACPA status (RF+ and ACPA+, 45.7%; RF+ or ACPA+, 43.8%; and FR− and ACPA−, 39.1%).

Conclusion

The 44% 2-year retention rate in the French ACTION cohort supports the usefulness of abatacept therapy. In this study, retention was not associated with treatment line, BMI, or antibody status.

Le texte complet de cet article est disponible en PDF.

Keywords : Abatacept, Biologic, Real-life study, Drug retention rate, Rheumatoid arthritis, National specificity